Overview

A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa

Status:
Terminated
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate a treatment to enhance the healing of acute and chronic nonhealing cutaneous wounds, such as the erosions experienced by patients with Epidermolysis Bullosa (EB), by the known activity of thymosin beta 4 (Tβ4). Funding Source - FDA Office of Orphan Product Development (OOPD).
Phase:
Phase 2
Details
Lead Sponsor:
RegeneRx Biopharmaceuticals, Inc.